Evidence map›Paper›PMID 35686164›Full record

ArticleMedecine tropicale et sante internationale2021

[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].

C I Razafindrazoto, A S Rasolonjatovo, N H Randriamifidy, S S Rabarioely, A L R Rakotozafindrabe, T H Rabenjanahary, S H Razafimahefa, R M Ramanampamonjy

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medecine tropicale et sante internationale, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

C I RazafindrazotoUnité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.
A S RasolonjatovoUnité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.
N H RandriamifidyUnité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.
S S RabarioelyUnité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.
A L R RakotozafindrabeUnité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.
T H RabenjanaharyUnité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.
S H RazafimahefaUnité de soins, de formation et de recherche, hépato-gastro-entérologie et de médecine interne, Fianarantsoa, Madagascar. Faculté de médecine de Fianarantsoa, Université de Fianarantsoa, Madagascar.
R M RamanampamonjyUnité de soins, de formation et de recherche, hépato-gastro-entérologie, Antananarivo, Madagascar. Faculté de médecine d'Antananarivo, Université d'Antananarivo, Madagascar.
Université de Fianarantsoa · MG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Our work aimed to assess the efficacy and safety of direct-acting antiviral drugs in the treatment of hepatitis C in Madagascar. Methods: This retrospective clinical study was carried out from March 2018 to February 2020 in the hepato-gastro-enterology department of the University Hospital Center Joseph Raseta de Befelatanana. Results: A total of 35 patients were included, out of which 24 received sofosbuvir/ledipasvir ± ribavirin, 10 sofosbuvir/ribavirin and one sofosbuvir/velpatasvir. Thirty-three patients were naïve to the treatment and 2 patients were initially treated with the sofosbuvir/ledipasvir combination. The sustained virologic response was 94% (33/35) in the general population, 23/25 in cirrhotic patients and 10/10 in non-cirrhotic patients. The sustained virologic response was 22/24 for sofosbuvir/ledipasvir ± ribavirin, 10/10 for sofosbuvir/ribavirin and 1/1 for sofosbuvir/velpatasvir. Adverse effects were observed in 13 patients, mainly asthenia and insomnia. Discussion: The small number of patients with hepatitis C treatments and their limited financial resources are the main limits of this survey. Conclusion: Direct-acting antivirals are effective and characterized by good tolerance in these Malagasy hepatitis C patients.

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsDrug Therapy, CombinationGenotypeHepacivirusHospitals, TeachingHumansMadagascarRetrospective StudiesRibavirinSofosbuvirAntiviral AgentsRibavirinSofosbuvirAntananarivoDirect-acting antiviral drugsHospitalIndian OceanMadagascarViral hepatitis C

Identifiers

PMID35686164
PMCPMC9128472
OpenAlexW4285745970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.